Cancer Medicine: There has been a steady rise in cancer cases recently. Factors such as a poor lifestyle, unhealthy diet, lack of physical activity, obesity, and smoking contribute to the development of cancer. In this context, there is significant news for cancer patients: to reduce the cost of cancer treatment, the central government has decided to tighten price controls on non-scheduled cancer drugs. According to government directives, the profit margin on the distribution and sale of these drugs will be capped at 30% of the Maximum Retail Price (MRP).
It is estimated that this move could lead to a reduction of up to 70% in the prices of certain drugs, potentially saving cancer patients approximately ₹2,500 crore annually. A statement from the Ministry of Chemicals and Fertilisers indicates that this measure—effective from November 9—is expected to lower the retail prices of these life-saving drugs by up to 70%, depending on their existing pricing structures.
Will the prices of cancer drugs decrease?
The government’s recent initiative aims to curb the high costs of cancer medications. By capping the profit margin on the distribution and sale of these drugs at 30% of the Maximum Retail Price (MRP), the government expects a substantial price reduction of up to 70%. This is projected to result in annual savings of approximately ₹2,500 crore for cancer patients.
Additional Information
The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilisers, stated that the National Pharmaceutical Pricing Authority (NPPA) discovered that, on average, a markup (profit margin) of about 170% was being applied to non-scheduled cancer drugs. In some instances, this markup was as high as 700% or even more. As a result, there was a significant gap between the pharmaceutical supply chain and the final price paid by the patient.
When purchasing medicines from retail pharmacies, hospital pharmacies, and online drug stores, consumers have observed substantial price variations. The new regulations aim to curb unjustified price hikes and alleviate the financial burden on patients.
This move builds upon the success of the National Pharmaceutical Pricing Authority’s (NPPA) 2019 pilot, ‘Trade Margin Rationalisation’ (TMR). Under that initiative, trade margins for 42 anti-cancer drugs were capped at 30 per cent, which led to a reduction of up to 90 per cent in the Maximum Retail Price (MRP) of 526 brands.